Figure 5.

Antitumor activity of PPAB001 in immunodeficient SK-OV-3 xenogeneic tumor-bearing mice

(A) Images of excised subcutaneous tumors treated with PPAB001, anti-CD24, or CV1-hFc are shown. (B) BALB/c nude mice were subcutaneously transplanted with SK-OV-3 cells and treated with PPAB001, anti-CD24, CV1-hFc, or hIgG (5 mg/kg) (n = 6). (C) After xenograft tumors were removed, these tumor masses were weighted. (D) The body weights of tumor-bearing mice were determined in the whole period of therapy. Mice were weighed at regular intervals during the whole period to monitor unspecific toxicity. (E) The changes of RBCs and hemoglobin response to treatment with PPAB001, anti-CD24, CV1-hFc, or hIgG. Data are shown as means ± SDs (n = 6), and statistical significance was determined by a Student’s t test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.